Evidence map›Paper›PMID 30019147›Full record

ReviewCurrent psychiatry reports2018

Neurotransmitter, Peptide, and Steroid Hormone Abnormalities in PTSD: Biological Endophenotypes Relevant to Treatment.

Ann M Rasmusson, Suzanne L Pineles

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Current psychiatry reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04468360 (Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD- Pharmacokinetic Studies), which is not on this map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04468360 phase2terminatednot on this mapstarted 2022, after this paper: background citation

Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD- Pharmacokinetic Studies

TypeinterventionalSponsorBoston UniversityRan2022 to 2025Enrolled11ConditionsPharmacokinetic Study, Post Traumatic Stress DisorderArmsPK-1 Good Manufacturing Practices (GMP) allopregnanolone (Allo) with Dexolve in 0.9% saline for infusion manufactured by the University of California, Davis, PK-2 GMP allopregnanolone (Allo) with Dexolve in 0.9% saline for infusion manufactured by the University of California, Davis.
3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 58 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Ann M RasmussonNational Center for PTSD, Women's Health Science Division, Department of Veterans Affairs, 150 South Huntington Avenue, Boston, MA, 02130, USA. ann.rasmusson@va.gov.
Suzanne L PinelesNational Center for PTSD, Women's Health Science Division, Department of Veterans Affairs, 150 South Huntington Avenue, Boston, MA, 02130, USA.
National Center for PTSD · USVA Boston Healthcare System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis review summarizes neurotransmitter, peptide, and other neurohormone abnormalities associated with posttraumatic stress disorder (PTSD) and relevant to development of precision medicine therapeutics for PTSD. RECENT

findingsAs the number of molecular abnormalities associated with PTSD across a variety of subpopulations continues to grow, it becomes clear that no single abnormality characterizes all individuals with PTSD. Instead, individually variable points of molecular dysfunction occur within several different stress-responsive systems that interact to produce the clinical PTSD phenotype. Future work should focus on critical interactions among the systems that influence PTSD risk, severity, chronicity, comorbidity, and response to treatment. Effort also should be directed toward development of clinical procedures by which points of molecular dysfunction within these systems can be identified in individual patients. Some molecular abnormalities are more common than others and may serve as subpopulation biological endophenotypes for targeting of currently available and novel treatments.

Indexed as

EndophenotypesComorbidityHormonesHumansNeuropeptidesNeurotransmitter AgentsSteroidsStress Disorders, Post-TraumaticHormonesNeuropeptidesNeurotransmitter AgentsSteroidsAdrenocorticotropin (ACTH)AllopregnanoloneCorticotropin releasing hormone (CRH)CortisolDehydroepiandrosterone (DHEA)EstradiolGABAGlucocorticoidsLong-term depression (LTD)Long-term potentiation (LTP)MonoaminesNeuropeptide Y (NPY)NeurosteroidsN-methyl-D-aspartate (NMDA) receptorProgesterone

Identifiers

PMID30019147
OpenAlexW2884268796

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.